S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:IMMP - IMMUTEP LTD/S Stock Price, Forecast & News

$2.15
+0.04 (+1.90 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$2.13
Now: $2.15
$2.20
50-Day Range
$1.61
MA: $1.77
$2.11
52-Week Range
$1.27
Now: $2.15
$3.23
Volume82,849 shs
Average Volume90,487 shs
Market Capitalization$83.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMMP
CUSIPN/A
Phone61-2-8315-7003

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.36 million
Book Value$0.51 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$83.85 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMMP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.


Forbes mag says this strategy "like finding money in the street" (Ad)


And Reuters magazine calls this type of trading "the new baby boomer hobby." An anonymous trader -- living at the base of the Smoky Mountains -- just released a free report revealing a step-by-step system to generating an extra $5,000 per month in income thanks to this trading strategy. The report is free until Sunday.

IMMUTEP LTD/S (NASDAQ:IMMP) Frequently Asked Questions

What is IMMUTEP LTD/S's stock symbol?

IMMUTEP LTD/S trades on the NASDAQ under the ticker symbol "IMMP."

What price target have analysts set for IMMP?

1 analysts have issued 12-month target prices for IMMUTEP LTD/S's stock. Their forecasts range from $4.00 to $4.00. On average, they expect IMMUTEP LTD/S's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 86.0% from the stock's current price. View Analyst Price Targets for IMMUTEP LTD/S.

What is the consensus analysts' recommendation for IMMUTEP LTD/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMMUTEP LTD/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMMUTEP LTD/S.

What are Wall Street analysts saying about IMMUTEP LTD/S stock?

Here are some recent quotes from research analysts about IMMUTEP LTD/S stock:
  • 1. Maxim Group analysts commented, "Immutep announced that it has received a £4M (~$5M) milestone payment from GlaxoSmithKline (GSK – NR) related to the initiation of dosing in the P2 trial for GSK2831781 (derived from IMP731) in ulcerative colitis. Immutep is eligible to receive up to £64M (~$79M) in development milestones as well as single digit royalties. Runway should extend into CY21. In addition to the $5M milestone, Immutep has also raised July financing. The financing consisted of a A$4M private placement for ~190M shares (~1.9M A$6M entitlement offer for ~290M shares (~2.9M ADR), both at A$0.021 per share (~ $1.42/ADR). We estimate the company has ~$18M of cash on hand. As such the company should be positioned to reach key catalysts which, if positive, should support a higher valuation." (9/24/2019)
  • 2. According to Zacks Investment Research, "Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia. " (9/5/2019)

Has IMMUTEP LTD/S been receiving favorable news coverage?

Press coverage about IMMP stock has trended somewhat positive on Friday, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IMMUTEP LTD/S earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for IMMUTEP LTD/S.

Who are some of IMMUTEP LTD/S's key competitors?

What other stocks do shareholders of IMMUTEP LTD/S own?

Who are IMMUTEP LTD/S's key executives?

IMMUTEP LTD/S's management team includes the folowing people:
  • Mr. Marc Voigt, Exec. Director, CEO, CFO & Chief Bus. Officer (Age 46)
  • Ms. Deanne Miller, COO, Gen. Counsel & Company Sec. (Age 42)
  • Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer (Age 64)
  • Mr. Jay R. Campbell, Chief Bus. Officer
  • Mr. David Fang, Fin. Director & Assistant Company Sec.

How do I buy shares of IMMUTEP LTD/S?

Shares of IMMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IMMUTEP LTD/S's stock price today?

One share of IMMP stock can currently be purchased for approximately $2.15.

How big of a company is IMMUTEP LTD/S?

IMMUTEP LTD/S has a market capitalization of $83.85 million and generates $5.36 million in revenue each year. View Additional Information About IMMUTEP LTD/S.

What is IMMUTEP LTD/S's official website?

The official website for IMMUTEP LTD/S is http://www.immutep.com/.

How can I contact IMMUTEP LTD/S?

IMMUTEP LTD/S's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company can be reached via phone at 61-2-8315-7003 or via email at [email protected]


MarketBeat Community Rating for IMMUTEP LTD/S (NASDAQ IMMP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  493
MarketBeat's community ratings are surveys of what our community members think about IMMUTEP LTD/S and other stocks. Vote "Outperform" if you believe IMMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel